Xanthine oxidoreductase mediates genotoxic drug‐induced autophagy and apoptosis resistance by uric acid accumulation and TGF‐β‐activated kinase 1 (TAK1) activation

Abstract Autophagy is a highly conserved cellular process that profoundly impacts the efficacy of genotoxic chemotherapeutic drugs. TGF‐β‐activated kinase 1 (TAK1) is a serine/threonine kinase that activates several signaling pathways involved in inducing autophagy and suppressing cell death. Xanthine oxidoreductase (XOR) is a rate‐limiting enzyme that converts hypoxanthine to xanthine, and xanthine to uric acid and hydrogen peroxide in the purine catabolism pathway. Recent studies showed that uric acid can bind to TAK1 and prolong its activation. We hypothesized that genotoxic drugs may induce autophagy and apoptosis resistance by activating TAK1 through XOR‐generated uric acid. Here, we report that gemcitabine and 5‐fluorouracil (5‐FU), two genotoxic drugs, induced autophagy in HeLa and HT‐29 cells by activating TAK1 and its two downstream kinases, AMP‐activated kinase (AMPK) and c‐Jun terminal kinase (JNK). XOR knockdown and the XOR inhibitor allopurinol blocked gemcitabine‐induced TAK1, JNK, AMPK, and Unc51‐like kinase 1 (ULK1) S555 phosphorylation and gemcitabine‐induced autophagy. Inhibition of the ATM‐Chk pathway, which inhibits genotoxic drug‐induced uric acid production, blocked gemcitabine‐induced autophagy by inhibiting TAK1 activation. Exogenous uric acid in its salt form, monosodium urate (MSU), induced autophagy by activating TAK1 and its downstream kinases JNK and AMPK. Gene knockdown or the inhibitors of these kinases blocked gemcitabine‐ and MSU‐induced autophagy. Inhibition of autophagy by allopurinol, chloroquine, and 5Z‐7‐oxozeaenol (5Z), a TAK1‐specific inhibitor, enhanced gemcitabine‐induced apoptosis. Our study uncovers a previously unrecognized role of XOR in regulating genotoxic drug‐induced autophagy and apoptosis and has implications for designing novel therapeutic strategies for cancer treatment.